Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 7/2012

01-05-2012 | Adis Drug Evaluation

Dihydroartemisinin/Piperaquine

A Review of its Use in the Treatment of Uncomplicated Plasmodium falciparum Malaria

Author: Gillian M. Keating

Published in: Drugs | Issue 7/2012

Login to get access

Abstract

Artemisinin-based combination regimens are recommended by WHO for the treatment of uncomplicated Plasmodium falciparum malaria. One such combination comprises the artemisinin derivative dihydroartemisinin and the bisquinolone piperaquine. Eurartesim® is the only dihydroartemisinin/piperaquine formulation that meets international good manufacturing practice standards. This article reviews the pharmacological properties of dihydroartemisinin and piperaquine, and the therapeutic efficacy and tolerability of dihydroartemisinin/piperaquine in the treatment of uncomplicated P. falciparum malaria.
A number of trials have shown dihydroartemisinin/piperaquine to be highly effective in the treatment of uncomplicated P. falciparum malaria. Two pivotal, randomized, open-label, multicentre trials demonstrated the Eurartesim® formulation of dihydroartemisinin/piperaquine to be noninferior to artesunate plus mefloquine in children and adults in Asia and noninferior to artemether/lumefantrine in children in Africa, in terms of polymerase chain reaction-corrected cure rates. In both trials, dihydroartemisinin/piperaquine recipients were significantly less likely than artesunate plus mefloquine recipients or artemether/lumefantrine recipients to experience reinfection. Gametocyte carriage was greater in patients receiving dihydroartemisinin/piperaquine than in those receiving comparator antimalarial regimens.
The Eurartesim® formulation of dihydroartemisinin/piperaquine was generally well tolerated in the treatment of uncomplicated P. falciparum malaria, and was associated with significantly less nausea, vomiting and dizziness than artesunate plus mefloquine. Although prolongation of the corrected QT interval has been reported in patients receiving dihydroartemisinin/piperaquine, there are currently no clinical data signalling that it is associated with clinically significant arrhythmias.
In conclusion, dihydroartemisinin/piperaquine is a valuable option for use in the first-line treatment of uncomplicated P. falciparum malaria.
Literature
1.
2.
German PI, Aweeka FT. Clinical pharmacology of artemisinin-based combination therapies. Clin Pharmacokinet 2008; 47 (2): 91–102PubMedCrossRef
3.
4.
Dondorp AM, Yeung S, White L, et al. Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol 2010 Apr; 8 (4): 272–80PubMed
5.
6.
Mayxay M, Keomany S, Khanthavong M, et al. A phase III, randomized, non-inferiority trial to assess the efficacy and safety of dihydroartemisinin-piperaquine in comparison with artesunate-mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. Am J Trop Med Hyg 2010; 83 (6): 1221–9PubMedCrossRef
7.
8.
Li W, Mo W, Shen D, et al. Yeast model uncovers dual roles of mitochondria in action of artemisinin. PLoS Genet 2005 Sep; 1 (3): e36
9.
Eckstein-Ludwig U, Webb RJ, van Goethem IDA, et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003 Aug 21; 424 (6951): 957–61PubMedCrossRef
10.
Davis TME, Hung T-Y, Sim I-K, et al. Piperaquine: a resurgent antimalarial drug. Drugs 2005; 65 (1): 75–87PubMedCrossRef
11.
Nsobya SL, Kiggundu M, Nanyunja S, et al. In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Antimicrob Agents Chemother 2010 Mar; 54 (3): 1200–6PubMedCrossRef
12.
Borrmann S, Sasi P, Mwai L, et al. Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS One 2011 Nov; 6 (11): e26005
13.
Briolant S, Henry M, Oeuvray C, et al. Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum. Antimicrob Agents Chemother 2010 Sep; 54 (9): 3537–44PubMedCrossRef
14.
Muangnoicharoen S, Johnson DJ, Looareesuwan S, et al. Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro. Antimicrob Agents Chemother 2009 Apr; 53 (4): 1362–6PubMedCrossRef
15.
Mwai L, Kiara SM, Abdirahman A, et al. In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob Agents Chemother 2009 Dec; 53 (12): 5069–73PubMedCrossRef
16.
Gargano N, Cenci F, Bassat Q. Antimalarial efficacy of piperaquine-based antimalarial combination therapies: facts and uncertainties. Trop Med Int Health 2011 Dec; 16 (12): 1466–73PubMedCrossRef
17.
Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009 Jul 30; 361 (5): 455–67PubMedCrossRef
18.
Noedl H, Se Y, Schaecher K, et al. Evidence of artemisinin-resistant malaria in western Cambodia [letter]. N Engl J Med 2008 Dec 11; 359 (24): 2619–20PubMedCrossRef
19.
Jambou R, Legrand E, Niang M, et al. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 2005 Dec 3; 366 (9501): 1960–3PubMedCrossRef
20.
Basco LK, Ringwald P. In vitro activities of piperaquine and other 4-aminoquinolines against clinical isolates of Plasmodium falciparum in Cameroon. Antimicrob Agents Chemother 2003 Apr; 47 (4): 1391–4PubMedCrossRef
21.
Some AF, Sere YY, Dokomajilar C, et al. Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodia-quine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob Agents Chemother 2010 May; 54 (5): 1949–54PubMedCrossRef
22.
Fivelman QL, Adagu IS, Warhurst DC. Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains. Antimicrob Agents Chemother 2007 Jun; 51 (6): 2265–7PubMedCrossRef
23.
Davis TME, Hamzah J, Ilett KF, et al. In vitro interactions between piperaquine, dihydroartemisinin, and other conventional and novel antimalarial drugs. Antimicrob Agents Chemother 2006 Aug; 50 (8): 2883–5PubMedCrossRef
24.
Valecha N, Phyo AP, Mayxay M, et al. An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. PLoS One 2010 Jul; 5 (7): e11880
25.
Bassat Q, Mulenga M, Tinto H, et al. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One 2009 Nov 17; 4 (11): e7871
26.
Mytton OT, Ashley EA, Peto L, et al. Electrocardiographic safety evaluation of dihydroartemisinin-piperaquine in the treatment of uncomplicated falciparum malaria. Am J Trop Med Hyg 2007 Sep; 77 (3): 447–50PubMed
27.
Karunajeewa H, Lim C, Hung T-Y, et al. Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin®) in Cambodian children and adults with malaria. Br J Clin Pharmacol 2004 Jan; 57 (1): 93–9PubMedCrossRef
28.
Ashley EA, Krudsood S, Phaiphun L, et al. Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. J Infect Dis 2004 Nov 15; 190 (10): 1773–82PubMedCrossRef
29.
Ashley EA, McGready R, Hutagalung R, et al. A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin Infect Dis 2005 Aug 15; 41 (4): 425–32PubMedCrossRef
30.
Borsini F, Crumb W, Pace S, et al. In vitro cardiovascular effects of dihydroartemisin-piperaquine combination: comparison with other antimalarials. Antimicrob Agents Chemother. Epub 2012 Mar 5
31.
32.
Nguyen DVH, Nguyen QP, Nguyen ND, et al. Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam. Antimicrob Agents Chemother 2009 Aug; 53 (8): 3534–7PubMedCrossRef
33.
Annerberg A, Lwin KM, Lindegardh N, et al. A small amount of fat does not affect piperaquine exposure in patients with malaria. Antimicrob Agents Chemother 2011 Sep; 55 (9): 3971–6PubMedCrossRef
34.
Sim I-K, Davis TME, Ilett KF. Effects of a high-fat meal on the relative oral bioavailability of piperaquine. Antimicrob Agents Chemother 2005 Jun; 49 (6): 2407–11PubMedCrossRef
35.
Chinh NT, Quang NN, Thanh NX, et al. Pharmacokinetics of the antimalarial drug piperaquine in healthy Vietnamese subjects. Am J Trop Med Hyg 2008 Oct; 79 (4): 620–3
36.
Hai TN, Hietala SF, Van Huong N, et al. The influence of food on the pharmacokinetics of piperaquine in healthy Vietnamese volunteers. Acta Trop 2008 Aug; 107 (2): 145–9PubMedCrossRef
37.
Hung TY, Davis TME, Ilett KF. Measurement of piperaquine in plasma by liquid chromatography with ultraviolet absorbance detection. J Chrom B Anal Tech Biomed Life Sci 2003 Jul 5; 791 (1-2): 93-101
38.
Tarning J, Ashley EA, Lindegardh N, et al. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother 2008 Mar; 52 (3): 1052–61PubMedCrossRef
39.
Tarning J, Lindegardh N, Sandberg S, et al. Pharmacokinetics and metabolism of the antimalarial piperaquine after intravenous and oral single doses to the rat. J Pharm Sci 2008 Aug; 97 (8): 3400–10PubMedCrossRef
40.
Grande T, Bernasconi A, Erhart A, et al. A randomised controlled trial to assess the efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Peru. PLoS One 2007 Oct; 2 (10): e1101
41.
Hien TT, Dolecek C, Mai PP, et al. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet 2004 Jan 3; 363 (9402): 18–22CrossRef
42.
Janssens B, van Herp M, Goubert L, et al. A randomized open study to assess the efficacy and tolerability of dihy-droartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health 2007 Feb; 12 (2): 251–9PubMedCrossRef
43.
Mayxay M, Thongpraseuth V, Khanthavong M, et al. An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People’s Democratic Republic (Laos). Trop Med Int Health 2006 Aug; 11 (8): 1157–65PubMed
44.
Tangpukdee N, Krudsood S, Thanachartwet W, et al. An open randomized clinical trial of Artekin® vs artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria. Southeast Asian J Trop Med Public Health 2005 Sep; 36 (5): 1085–91PubMed
45.
Nambozi M, van Gerrtruyden J-P, Hachizovu S, et al. Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malar J 2011 Feb 28; 10: 50
46.
The 4ABC Study Group. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med 2011 Nov; 8 (11): e1001119
47.
Mens PF, Sawa P, van Amsterdam SM, et al. A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya. Malar J 2008 Nov 18; 7: 237
48.
Adam I, Salah MT, Eltahir HG, et al. Dihydroartemisinin-piperaquine versus artemether-lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in central Sudan. Ann Trop Med Parasitol 2010; 104 (4): 319–26PubMedCrossRef
49.
Kamya MR, Yeka A, Bukirwa H, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials 2007 May; 2 (5): e20
50.
Yavo W, Faye B, Kuete T, et al. Multicentric assessment of the efficacy and tolerability of dihydroartemisinin-piperaquine compared to artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa. Malaria J 2011 Jul 20; 10: 198
51.
Yeka A, Dorsey G, Kamya MR, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One 2008 Jun; 3 (6): e2390
52.
Zongo I, Dorsey G, Rouamba N, et al. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis 2007 Dec 1; 45 (11): 1453–61PubMedCrossRef
53.
Arinaitwe E, Sandison TG, Wanzira H, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis 2009; 49 (11): 1629–37PubMedCrossRef
54.
Song J, Socheat D, Tan B, et al. Randomized trials of artemisinin-piperaquine, dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area. Malaria J 2011 Aug 10; 10: 231
55.
Karema C, Fanello CI, Van Overmeir C, et al. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin®) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Trans R Soc Trop Med Hyg 2006 Dec; 100 (12): 1105–11PubMedCrossRef
56.
Thanh NX, Trung TN, Phong NC, et al. Open label randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in central Vietnam. Trop Med Int Health 2009 May; 14 (5): 504–511PubMedCrossRef
57.
Trung TN, Tan B, Van Phuc D, et al. A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria. Chin J Integr Med 2009 Jun; 15 (3): 189–92PubMedCrossRef
58.
Carrara VI, Zwang J, Ashley EA, et al. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One 2009 Feb; 4 (2): e4551PubMedCrossRef
59.
Rogers WO, Sem R, Tero T, et al. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malar J 2009 Jan 12; 8: 10PubMedCrossRef
60.
Karunajeewa HA, Mueller I, Senn M, et al. A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med 2008 Dec 11; 359 (24): 2545–57PubMedCrossRef
61.
Tarning J, Zongo I, Some FA, et al. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther 2012 Mar; 91 (3): 497–505PubMedCrossRef
62.
63.
Douglas NM, Anstey NM, Angus BJ, et al. Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 2010 Jun; 10 (6): 405–16PubMedCrossRef
64.
Myint HY, Ashley EA, Day NP, et al. Efficacy and safety of dihydroartemisinin-piperaquine. Trans R Soc Trop Med Hyg 2007 Sep; 101 (9): 858–66PubMedCrossRef
65.
Zwang J, Ashley EA, Karema C, et al. Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS One 2009 Jul; 4 (7): e6358PubMedCrossRef
66.
67.
Antinori S, Cigardi B, Galimberti L, et al. Diagnosis and therapy for hospitalized imported malaria in adults in Italy. J Travel Med 2011; 18 (6): 379–85PubMedCrossRef
68.
Kelesidis T, Kelesidis I, Rafailidis PI, et al. Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. J Antimicrob Chemother 2007 Aug; 60 (2): 214–36PubMedCrossRef
69.
70.
Nankabirwa J, Cundill B, Clarke S, et al. Efficacy, safety, and tolerability of three regimens for prevention of malaria: a randomized, placebo-controlled trial in Ugandan schoolchildren. PLoS One 2010 Oct; 5 (10): e13438
71.
Cisse B, Cairns M, Faye E, et al. Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children. PLoS One 2009 Sep; 4 (9): e7164
72.
Bojang K, Akor F, Bittaye O, et al. A randomised trial to compare the safety, tolerability and efficacy of three drug combinations for intermittent preventive treatment in children. PLoS One 2010 Jun; 5 (6): e11225
73.
Lwin KM, Phyo AP, Tarning J, et al. A randomised, doubleblind, placebo controlled trial of monthly versus second monthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria. Antimicrob Agents Chemother 2012 Mar; 56 (3): 1571–7PubMedCrossRef
74.
Phyo AP, Lwin KM, Price RN, et al. Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. Clin Infect Dis 2011 Nov 15; 53 (10): 977–84PubMedCrossRef
75.
Awab GR, Pukrittayakamee S, Imwong M, et al. Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial. Malaria J 2010 Apr 21; 9: 105
76.
Poespoprodjo JR, Fobia W, Kenangalem E, et al. Adverse pregnancy outcomes in an area where multidrug-resistant Plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis 2008 May 1; 46 (9): 1374–81PubMedCrossRef
77.
Rijken MJ, McGready R, Boel ME, et al. Dihydroartemisinin-piperaquine rescue treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy: a preliminary report. Am J Trop Med Hyg 2008; 78 (4): 543–5PubMed
78.
Rijken MJ, McGready R, Phyo AP, et al. Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria. Antimicrob Agents Chemother 2011 Dec; 55 (12): 5500–6PubMedCrossRef
79.
Tarning J, Rijken MJ, McGready R, et al. Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and non-pregnant women with uncomplicated malaria. Antimicrob Agents Chemother 2012 Apr; 56 (4): 1997–2007PubMedCrossRef
Metadata
Title
Dihydroartemisinin/Piperaquine
A Review of its Use in the Treatment of Uncomplicated Plasmodium falciparum Malaria
Author
Gillian M. Keating
Publication date
01-05-2012
Publisher
Springer International Publishing
Published in
Drugs / Issue 7/2012
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/11203910-000000000-00000

Other articles of this Issue 7/2012

Drugs 7/2012 Go to the issue

Adis Drug Profile

Bevacizumab Combination Therapy

Adis Drug Profile

Bevacizumab in Ovarian Cancer

Review Article

Patent Ductus Arteriosus in Premature Neonates

Therapy In Practice

Assessment and Medication Management of Paediatric Obsessive-Compulsive Disorder

Correspondence

The Author’s Reply

Current Opinion

Coming to Terms with Nonsteroidal Anti-Inflammatory Drug Gastropathy